Pharmamarketeer

Vertex lands blockbuster triple combo nod for CF drug Trikafta—5 months early

The triple combo era in cystic fibrosis is here thanks to Vertex’ new OK. Five months ahead of schedule, the FDA green-lighted Trikafta for the treatment of CF patients over the age of 12 with either one or two copies of the delF508 CFTR gene mutation.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl